D 565

Drug Profile

D 565

Alternative Names: D565

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 17 Feb 2017 Phase-I clinical trials in Undefined indication in South Korea (unspecified route)
  • 13 Feb 2017 Chong Kun Dang plans a phase I trial for an Undefined indication in South Korea (NCT03034486)
  • 25 Jan 2017 Preclinical trials in Undefined indication in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top